
Opinion|Videos|August 1, 2024
Future Possibilities in IPF Treatment
Author(s)Steven D. Nathan, MD
Dr Nathan discusses the trajectory of IPF management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis (IPF)?
- Cell-based therapies represent another modality being explored for IPF. What is the potential impact of this type of treatment?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
2
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
3
IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs
4
Complicated UTI Care Strained by Unclear Goals, Access Gaps
5



